Aurora Cannabis (ACB, Financials) reported record-breaking financial results for the third quarter of fiscal 2025, driven by strong international medical cannabis sales and increased operational efficiency.
Driven primarily by its global medical cannabis division, which saw revenue surge 51% YoY to $68.1 million, the firm reported total net revenue of $88.2 million, a 37% year-over-year increase. Strong sales in Australia, Germany, Poland, and the United Kingdom drove international medical cannabis revenue up 112%, accounting for 60% of the company's total medical cannabis revenue.
Fueled by sustained cost reductions, improved pricing, and increased production efficiency, the adjusted gross margin on medical cannabis rose to 74%, up from 63% a year earlier. As Aurora prioritized higher-margin medical cannabis sales, the company's consumer cannabis revenue declined 15% YoY to $9.9 million.
Reflecting a 342% YoY increase, Aurora also reported record net income of $31.2 million and record adjusted EBITDA of $23.1 million, up 316%. The company generated positive free cash flow of $27.4 million, meeting a key profitability milestone.
Supported by expanded capacity and increased sales of high-margin ornamental plants, Aurora's plant propagation business posted $8.9 million in revenue, up 22% YoY. Maintaining a debt-free cannabis business, the company ended the quarter with $180 million in cash.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。